Brief: Rocket Pharmaceuticals Presents Preliminary Data From Phase 1 Clinical Trial of RP-A601 For PKP2 Arrhythmogenic Cardiomyopathy At 28th Annual Meeting Of The American Society Of Gene And Cell Therapy
15/05/2025 21:09
May 15 (Reuters) - Rocket Pharmaceuticals Inc RCKT.O: ROCKET PHARMACEUTICALS PRESENTS PRELIMINARY DATA FROM PHASE 1 CLINICAL TRIAL OF RP-A601 FOR PKP2 ARRHYTHMOGENIC CARDIOMYOPATHY AT 28TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE AND CELL THERAPY Source text: ID:nBw8kgdyPa Further company coverage: RCKT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket Pharmaceuticals
See all newsRocket Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Rocket Pharmaceuticals posts Q2 profit helped by PRV sale
Brief: Rocket Pharmaceuticals Q2 EPS USD 1.08